pBK-VQR-BE3 Citations (4)

Originally described in: Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions.
Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR Nat Biotechnol. 2017 Feb 13. doi: 10.1038/nbt.3803. PubMed Journal

---

Articles Citing pBK-VQR-BE3

Articles
Introduction of pathogenic mutations into the mouse Psen1 gene by Base Editor and Target-AID. Sasaguri H, Nagata K, Sekiguchi M, Fujioka R, Matsuba Y, Hashimoto S, Sato K, Kurup D, Yokota T, Saido TC. Nat Commun. 2018 Jul 24;9(1):2892. doi: 10.1038/s41467-018-05262-w. PubMed
CRISPR-SKIP: programmable gene splicing with single base editors. Gapinske M, Luu A, Winter J, Woods WS, Kostan KA, Shiva N, Song JS, Perez-Pinera P. Genome Biol. 2018 Aug 15;19(1):107. doi: 10.1186/s13059-018-1482-5. PubMed
Screening of CRISPR/Cas base editors to target the AMD high-risk Y402H complement factor H variant. Tran MTN, Khalid MKNM, Pebay A, Cook AL, Liang HH, Wong RCB, Craig JE, Liu GS, Hung SS, Hewitt AW. Mol Vis. 2019 Mar 16;25:174-182. eCollection 2019. PubMed
Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro. Guyon A, Rousseau J, Begin FG, Bertin T, Lamothe G, Tremblay JP. Mol Ther Nucleic Acids. 2021 Mar 1;24:253-263. doi: 10.1016/j.omtn.2021.02.032. eCollection 2021 Jun 4. PubMed

If you have published an article using this material, please email us at to have your article added to this page.